Novo's full results for Wegovy in children ages 6 to under 12 with obesity are a meaningful step. In a trial of 167 kids, the injection lowered BMI by an estimated 19.7 percentage points compared with placebo at 68 weeks when patients stayed on treatment, and by an estimated 16.2 percentage points when all children were counted, including those who stopped. Those are large, concrete numbers, and they matter for a group that, as the report notes, has had no approved medication options.
The reason this matters is the stakes the report describes. Childhood obesity can carry cardiovascular, metabolic and psychosocial consequences, and it can extend into adulthood with earlier and more severe complications. Nearly half the children in the trial already had at least one obesity-related complication, such as high blood pressure, high cholesterol or sleep apnea. Treating a disease that starts this early is an argument worth taking seriously.
Still, the report itself points to the limits of what has been shown. The headline BMI figures assume patients stayed on treatment, and the all-patients figure is smaller. Every child also received lifestyle modifications, including a reduced-calorie diet and increased physical activity, so the drug's effect cannot be separated cleanly from that support in this design. Novo said safety was consistent with adult trials and that it saw no concerns related to growth or pubertal development, which is reassuring but needs continued monitoring in a population this young.
The most important caveat comes from Dr. Andrea Traina, Novo's medical director lead of obesity, who acknowledged that the two-year study does not establish whether earlier treatment changes the long-term trajectory of the disease, or what treatment and maintenance look like as children grow up. She called that an evidence gap. Her candor should be the starting point for coverage and for regulators, not a footnote.
My conclusion is that regulators and families should welcome this data while demanding longer follow-up before treating it as settled. Approval decisions for the youngest patients should rest on durable outcomes, not only on a drop in BMI, and independent researchers should be able to examine the full dataset. Good news for children with obesity is worth reporting; it is also worth reporting the questions still unanswered.